Delayed treatment with an IV dose of 1 mg/kg of the TfRMAb-GDNF fusion protein produced a 30% reduction in cortical stroke volume, and the combined delayed treatment of 1 mg/kg of the TfRMAb-GDNF and 1 mg/kg of the TfRMAb-TNFR fusion proteins produced a 69% reduction in cortical stroke volume in the reversible MCAO model of stroke in mice (Sumbria et al, 2013b). Here, TNFRSF1A is linked to stroke disorder.